drugset
drugset / Trial / NCT00881426

To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions

NCT00881426 ↗

Phase 1 Completed 26 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Cefzil 500 mg Cefprozil tablets under fasting conditions.

Timeline

Start
2004-03
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CEFPROZIL ANHYDROUS, (E)- Small molecule 500 mg —

Indications

No indication recorded.